NOTE:In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the U.S. Food and Drug Administration (FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines.
*Note: If no residual disease after preoperative therapy or no preoperative therapy, complete up to one year of HER2-targeted therapy with trastuzumab with or without pertuzumab after completing planned chemotherapy regimen course. If residual disease is present after preoperative therapy and ado-trastuzumab emtansine (Kadcyla) is discontinued for toxicity, then trastuzumab with or without pertuzumab to complete one year of therapy can be used.
**Note:Men with breast cancer should be treated similarly to postmenopausal women, except that use of an aromatase inhibitor is ineffective without concomitant suppression of testicular steroidogenesis.
Do not substitute trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, or Trazimera) or trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) for or with ado-trastuzumab emtansine (Kadcyla) or fam-trastuzumab deruxtecan-nxki (Enhertu).